Abstract:Seasonal allergic conjunctivitis (SAC) is caused by seasonal allergens and usually manifests as ocular itching and bulbar conjunctival injection (redness). Treatment options for SAC include corticosteroids and dual-acting antihistamine and mast-cell stabilizers.Our objective was to compare the efficacy and tolerability of loteprednol etabonate (LE), a C-20 ester-based corticosteroid, with those of olopatadine, a dual-acting antihistamine mast-cell stabilizer, in Chinese patients.This was a multicenter, randomized, investigator-masked, parallel group study. Patients with acute SAC experiencing grade 4 ocular itching and grade 2 or higher bulbar conjunctival injection received either LE suspension 0.2% QID at 4-hour intervals or olopatadine solution 0.1% BID at 6- to 8-hour intervals bilaterally for 15 days. Primary efficacy end points included the change from baseline (CFB) in ocular itching and bulbar conjunctival injection at day 15. The primary analysis tested the noninferiority of LE suspension 0.2% to olopatadine solution 0.1%. Tolerability outcomes included the incidence of adverse events (AEs), biomicroscopy findings, visual acuity, and intraocular pressure.A total of 300 patients were randomly assigned, and 293 were included in the per-protocol population (LE, n = 147; olopatadine, n = 146). Mean (SD) CFB at day 15 in the LE and olopatadine treatment groups, respectively, was -3.74 (0.47) and -3.28 (0.91) for ocular itching and -1.91 (0.52) and -1.71 (0.59) for bulbar conjunctival injection. The 95% CI for the differences in CFB in ocular itching (-0.59 to -0.27) and bulbar conjunctival injection (-0.27 to -0.08) was less than the prespecified noninferiority limit of 0.3. Treatment differences in CFB were significantly better with LE compared with olopatadine for both end points (P ≤ 0.0006). Ocular AEs were few and similar between treatment groups. There were no clinically significant biomicroscopy or visual acuity findings, and no patient experienced a clinically significant increase in intraocular pressure (≥10 mm Hg).Results of this investigator-masked study with Chinese patients suggest LE suspension 0.2% was noninferior to olopatadine solution 0.1% for the treatment of SAC. Both LE suspension 0.2% and olopatadine solution 0.1% were well tolerated. ClinicalTrials.gov identifier: NCT01435460.

Evaluation of the Efficacy of Olopatadine Hydrochloride in the Treating Allergic Rhinitis:A Multicenter,Randomized,Double-blind,Double-dummy Study

Clinical Randomized Controlled Trials of Levocetirizine in Treatment of 72 Patients with Anaphylactic Rhinitis

Efficacy and Safety of Cetirizine-Pseudoephedrine Sustained-Release Tablets in the Treatment of Seasonal and Perennial Allergic Rhinitis

Randomized Controlled Clinical Trial on Azelastine Hydrochloride Tablet Versus Loratadine in the Treatment of Allergic Rhinitis

Treatment of Allergic Rhinitis with Fexofenadine Hydrochloride: a Multicenter Clinical Trial

Studies on efficacy and safety of fexofenadine in treating seasonal allergic rhinitis and chronic idiopathic urticaria

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study

Efficacy and Safety of Mizolastine in the Treatment of Perennial Allergic Rhinitis

Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

Evaluation of the Efficacy and Safety of Desloratadine in Treating Allergic Rhinitis

Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

A COMPARATIVE STUDY OF OLOPATADINE 0.01% COMBINED FLUOROMETHOLONE 0.1% TREATMENT VERSUS OLOPATADINE 0.01% COMBINED KETOROLAC 0.4% TREATMENT IN ALLERGIC CONJUNCTIVITIS IN SAROJINI DEVI EYE HOSPITAL

Bepotastine besilate for the treatment of chronic urticaria: a multicenter, double-blind, randomized,parallel-controlled study

Acupuncture for Moderate to Severe Allergic Rhinitis: A Non-Randomized Controlled Trial.

Assessment of the efficacy of olopatadine 0.1% in the treatment of vernal keratoconjunctivitis in terms of clinical improvement based on total ocular symptom score and ocular surface disease index

Pharmacokinetics of Orally Administered Single- and Multiple-Dose Olopatadine in Healthy Chinese Subjects

[Efficacy of Intranasal Antihistamine in the Treatment of Allergic Rhinitis: a Meta-Analysis].

Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis

Efficacy and safety of pemirolast potassium in comparison with tranilast for bronchial asthma and allergic rhinitis:a multicenter,randomized,double-blind,double-dummy,parallel-group trial

Efficacy and Safety of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis: a Randomized Controlled Trial

Efficacy of Acupuncture on Moderate and Severe Allergic Rhinitis